Treatment of MOPP‐refractory Hodgkin‐s disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine

Lawrence H. Einhorn, Stephen D. Williams, Eugene E. Stevens, William H. Bond, Linda Chenoweth

Research output: Contribution to journalArticle

15 Scopus citations

Abstract

Eighteen patients with advanced Hodgkin's disease, refractory to combination chemotherapy with nitrogen mustard, vincristine, prednisone, and procarbazine (MOPP), were treated with vinblastine, doxorubicin (Adriamycin), bleomycin, CCNU, and dacarbazine (DTIC) (VABCD). Fifteen patients had Stage IV disease and 11 had systemic symptoms. Although hematologic toxicity was considerable, there was no drug related mortality. Eight patients achieved a complete remission (CR), and five are currently in a continuous CR of five, 24, 30, 34, and 36 months duration, respectively. An additional patient had a 30-month CR and relapsed with localized lymphadenopathy and is currently disease-free following involved-field radiotherapy 46 months from initiation of VABCD. This study suggests that long-term disease-free survival and potential cure can be achieved with VABCD in MOPP-refractory Hodgkin's disease.

Original languageEnglish (US)
Pages (from-to)1348-1352
Number of pages5
JournalCancer
Volume51
Issue number8
DOIs
StatePublished - Apr 15 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Treatment of MOPP‐refractory Hodgkin‐s disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine'. Together they form a unique fingerprint.

  • Cite this